Nov 7, 2022 · Innovations in pathology, molecular biology and drug development have enabled HER2-positive breast cancer (BC), a historically aggressive subtype, to become one with impressive outcomes.

Mar 12, 2020 · Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2 + breast cancer.

As the monoclonal antibody binds its target, it brings the chemotherapy agent close to the cancer cell where it is released and can exert its toxic effect while sparing healthy cells. Antibody-drug conjugates currently used to treat HER2-positive breast cancer are ado-trastuzumab emtansine (TDM-1/Kadcyla®) and trastuzumab deruxtecan (Enhertu ...

HER2 amplifies the signal provided by other receptors of the HER family by forming heterodimers. The essential role of HER2 in the HER signaling network led to the development of anti-HER2 monoclonal antibodies (MAbs) for cancer therapy.

We studied a large panel of human HER2 antibodies to identify the characteristics that make them most suitable for an ADC approach. As a model toxin, amenable to in vitro high-throughput screening, we employed Pseudomonas exotoxin A (ETA’) fused to an anti-kappa light chain domain antibody.

Human epidermal growth factor receptor 2–positive (HER2 +) breast cancer accounts for ~25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2 + breast cancer.

Jun 1, 2001 · Trastuzumab, a MAb that is effective in the therapy of breast tumors that overexpressing HER2, has a direct inhibitory effect on basal and APMA-induced HER2 shedding. In contrast, 2C4, another MAb against HER2 ectodomain, does …

May 2, 2024 · Overexpression of human epidermal growth factor receptor 2 (HER2) in breast and gastric cancers is associated with a poor prognosis, making it an important therapeutic target. Here, we establish a novel cancer-specific anti-HER2 antibody, H 2 Mab-214.

Nov 28, 2017 · HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer.

Feb 16, 2021 · We recently produced a new humanized anti-HER2 mAb, hersintuzumab, which recognizes a different epitope than trastuzumab and pertuzumab on HER2. This mAb, in combination with trastuzumab, exhibits more potent anti …